Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Combivir

Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-088512 · Präparat HOS-083663

Drugs by Therapeutic Area Interaction Recommendation Geometric mean change (%) concerning co- (Possible mechanism) administration ANTIRETROVIRAL MEDICINAL PRODUCTS Didanosine/Lamivudine Interaction not studied. No dosage adjustment necessary. Didanosine /Zidovudine Interaction not studied. Stavudine/Lamivudine Interaction not studied. Combination not Stavudine/Zidovudine In vitro antagonism of anti-HIV recommended. activity between stavudine and zidovudine could result in decreased efficacy of both drugs. ANTI-INFECTIVE PRODUCTS Atovaquone/Lamivudine Interaction not studied. As only limited data available Atovaquone/Zidovudine Zidovudine AUC 33% the clinical significance is (750 mg twice daily with Atovaquone AUC  unknown. food/200 mg thrice daily) Clarithromycin/Lamivudine Interaction not studied. Separate administration of Clarithromycin/Zidovudine Zidovudine AUC 12% Combivir and clarithromycin (500 mg twice daily/100 mg by at least 2 hours every 4 hours) Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% No Combivir dosage (Co-trimoxazole)/Lamivudine adjustment necessary, unless (160 mg/800 mg once daily for Trimethoprim: AUC  patient has renal impairment 5 days/300 mg single dose) Sulfamethoxazole: AUC  (See Section 4.2).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) atovaquone (HOS-086266) trimethoprim (HOS-085184) stavudine (HOS-088080) clarithromycin (HOS-084517) didanosine (HOS-085836)